Oppenheimer Equities Analysts Increase Earnings Estimates for Syros Pharmaceuticals Inc (NASDAQ:SYRS)

Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Equities research analysts at Oppenheimer raised their Q1 2018 earnings per share estimates for Syros Pharmaceuticals in a report released on Monday, according to Zacks Investment Research. Oppenheimer analyst L. Cann now anticipates that the company will earn ($0.59) per share for the quarter, up from their prior estimate of ($0.88). Oppenheimer has a “Buy” rating and a $28.00 price target on the stock. Oppenheimer also issued estimates for Syros Pharmaceuticals’ Q2 2018 earnings at ($0.72) EPS, Q3 2018 earnings at ($0.74) EPS, Q4 2018 earnings at ($0.77) EPS, FY2018 earnings at ($2.83) EPS, FY2019 earnings at ($2.12) EPS, FY2020 earnings at ($0.19) EPS and FY2021 earnings at $1.70 EPS.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Wednesday, November 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.53).

A number of other analysts have also recently weighed in on SYRS. Zacks Investment Research cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Roth Capital initiated coverage on shares of Syros Pharmaceuticals in a research note on Monday, October 23rd. They set a “neutral” rating and a $15.00 price target for the company. Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 price target on shares of Syros Pharmaceuticals in a research note on Tuesday, October 31st. JMP Securities upgraded shares of Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a research note on Thursday, September 28th. Finally, ValuEngine cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $22.23.

Syros Pharmaceuticals (NASDAQ SYRS) opened at $10.80 on Thursday. Syros Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $24.38. The stock has a market cap of $276.90, a price-to-earnings ratio of -5.37 and a beta of -3.32.

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of Syros Pharmaceuticals by 11.9% in the 2nd quarter. FMR LLC now owns 3,926,998 shares of the company’s stock valued at $63,185,000 after purchasing an additional 418,061 shares in the last quarter. Redmile Group LLC increased its holdings in shares of Syros Pharmaceuticals by 2.2% in the 2nd quarter. Redmile Group LLC now owns 973,260 shares of the company’s stock valued at $15,660,000 after purchasing an additional 20,520 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Syros Pharmaceuticals by 189.6% in the 2nd quarter. Vanguard Group Inc. now owns 382,603 shares of the company’s stock valued at $6,156,000 after purchasing an additional 250,507 shares in the last quarter. State Street Corp increased its holdings in shares of Syros Pharmaceuticals by 176.7% in the 2nd quarter. State Street Corp now owns 169,497 shares of the company’s stock valued at $2,728,000 after purchasing an additional 108,250 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Syros Pharmaceuticals by 15.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 126,530 shares of the company’s stock valued at $1,926,000 after purchasing an additional 17,330 shares in the last quarter. Institutional investors own 57.96% of the company’s stock.

In other news, insider Jeremy P. Springhorn bought 15,000 shares of Syros Pharmaceuticals stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $9.08 per share, for a total transaction of $136,200.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Srinivas Akkaraju bought 109,774 shares of Syros Pharmaceuticals stock in a transaction dated Thursday, December 14th. The stock was purchased at an average price of $9.03 per share, with a total value of $991,259.22. The disclosure for this purchase can be found here. 33.60% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/01/20/brokers-offer-predictions-for-syros-pharmaceuticals-incs-q1-2018-earnings-syrs.html.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.

Get a free copy of the Zacks research report on Syros Pharmaceuticals (SYRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply